MCAS and Brain Fog: What the Evidence Shows

Mast cells release mediators that affect blood vessels, nerves, and immune cells. So researchers have several plausible ways to link mast-cell activation with cognitive symptoms. That doesn't mean researchers have shown each of these links in people with MCAS, or that all patients share the same one.

Mast-cell mediators and the brain

Mast cells live near blood vessels and nerves, including in the brain and spinal cord. Histamine, tryptase, prostaglandins, leukotrienes, and cytokines can affect vascular tone and immune signaling. Laboratory and animal research has examined how mast-cell mediators may influence the blood-brain barrier and microglia, the immune cells that support and protect brain tissue. These findings make the biology plausible, but they are not proof that a person's cognitive symptoms come from a damaged blood-brain barrier or chronically activated microglia.

Brain imaging findings in mastocytosis

Boddaert's team compared 39 people with mastocytosis who had psychological or thinking complaints with 33 healthy controls. MRI found structural changes in 49% of the mastocytosis group, mostly small changes in white matter (tissue connecting brain areas). The study also found a blood-flow difference in the putamen, a deep brain region. The authors called for more research on how this happens and whether the finding is specific to mastocytosis.

Blood flow and small-fiber neuropathy

Novak's team tested people with MCAS or hereditary alpha-tryptasemia and neurological symptoms, using tilt tests, brain blood-flow measurements, skin biopsies and other heart-rate and blood-pressure checks. In the MCAS group, brain blood flow was 20.8% slower than in controls when upright. In 81% of that group, biopsies showed fewer nerve fibers, which fits small-fiber neuropathy. The tests found mild-to-moderate dysautonomia (heart-rate and blood-pressure problems).

This gives a concrete reason to ask whether cognitive symptoms worsen while upright, during heat, after exertion, or with lightheadedness. It is not a reason to assume that reduced brain blood flow is the cause of every episode.

Objective cognitive testing in mastocytosis

In a study of 57 people with mastocytosis, 22 people, or 38.6%, had objective impairment in memory or attention on the Wechsler Clinical Memory Scale. Working memory was affected most often, followed by immediate auditory memory. The impairment was not associated with depression scores, age, or education level in that sample. This is evidence that cognitive problems can occur in mastocytosis; it is not a prevalence estimate for MCAS or for the general population.

A large MCAS survey

Weinstock and colleagues compared questionnaires from 553 people with MCAS and 558 controls. The MCAS group reported higher rates of many neurological and psychiatric conditions, including cognitive dysfunction, fatigue, insomnia, migraine-like headaches, and attention-related diagnoses. Respondents also rated how much each treatment helped. On average, they gave antihistamines 6.3 out of 10, low-dose naltrexone 5.6, and benzodiazepines 5.6.

The survey shows how many different neurological and psychiatric symptoms respondents reported. Questionnaires cannot show that MCAS caused each condition, and self-rated treatment benefit cannot show that one treatment works for everyone.

A small treatment case series

A 2023 case series described eight people with MCAS and significant neuropsychiatric symptoms. All eight reported improvement after mast-cell-directed treatment, and six had autonomic disorders. The study had no control group and only eight cases, so it raises a treatment question but doesn't answer it.

MCAS and histamine intolerance can cause similar symptoms, but they're thought to be different problems. In MCAS, mast cells release chemicals when they shouldn't, or too much of them. Histamine intolerance usually means your body has trouble breaking down histamine from food and drink. It's often linked to diamine oxidase, the gut enzyme that does that job. A reaction after eating can fit more than one explanation.

What the MCAS criteria are trying to establish

A suspected MCAS diagnosis is not based on brain fog, a high symptom score, or improvement after one medication. Consensus criteria generally look for three pieces of evidence. Do symptoms of mast-cell mediator release recur in at least two organ systems? Does a validated mediator rise measurably during an episode? Do symptoms respond to treatment aimed at mast-cell mediators? The diagnostic literature also warns that many conditions can mimic MCAS and that overdiagnosis is a concern.

So one normal test result doesn't settle every question. For the same reason, a symptom list alone can't confirm MCAS. The timing of the sample, the laboratory method, the person's baseline level, and what was happening during the episode all matter.

ADHD and MCAS can occur in the same person. Lifelong attention symptoms that occur across settings are evaluated differently from new or sharply fluctuating problems that rise during physical episodes. Both deserve attention, and one diagnosis isn't a reason to dismiss the other.

Long COVID and MCAS can share cognitive symptoms, fatigue, heart-rate changes, gastrointestinal symptoms, and orthostatic intolerance. A 2023 review discussed immune dysfunction and mast-cell activation as one possible part of Long COVID. That doesn't prove that MCAS causes Long COVID, or that every case of Long COVID brain fog is a mast-cell problem. The timing of the infection, the symptoms in other systems, and objective testing still matter.

See our Long COVID and ME/CFS cause page for the wider differential.

POTS and MCAS can occur together, but one doesn't prove the other. If cognitive symptoms rise with standing, dizziness, palpitations, faintness, heat intolerance, or exercise intolerance, the evaluation may need orthostatic vital signs or formal autonomic testing. If food is the main trigger with no other mast-cell symptoms, the evaluation still needs to consider other explanations.

See our POTS cause page for information about orthostatic symptoms and testing.

Treatment depends on the diagnosis, the symptoms being treated, other conditions, and the person's response. The studies above do not justify a universal MCAS regimen. They do support discussing the following categories with the clinician managing the evaluation.

An appointment record works better when it's short and specific. Write down the date, the first symptom, and when cognitive symptoms began. Add the food or exposure beforehand, your position, other body symptoms, duration, sleep, medicines, and what changed the episode. If symptoms start the next morning, record that delay, since they may still be related.

Questions for the evaluation

• Do the episodes involve more than one organ system at the same time?
• Is there a repeatable relationship with food, heat, exertion, stress, standing, or a medicine?
• Which alternative causes of new or worsening cognitive symptoms still need assessment?
• Would mediator testing during an episode, autonomic testing, neuropsychological testing, or another test answer a specific open question?
• Could a current medicine, including a sedating antihistamine, be worsening sleepiness or slowed thinking?

The aim is to match each test to a specific question, not to run every possible test. It's also to keep MCAS, histamine intolerance, mastocytosis, POTS, migraine, sleep disorders, medication effects, and other causes from being mixed up.

Most evidence here comes from mastocytosis studies, MCAS questionnaires, small case series, or selected people sent for neurological testing. They show people do get thinking and autonomic symptoms.

1. 1. Moura DS, Sultan S, Georgin-Lavialle S, et al. Evidence for cognitive impairment in mastocytosis: prevalence, features and correlations to depression. PLoS One. 2012. PMID 22745762.
2. 2. Boddaert N, Salvador A, Chandesris MO, et al. Neuroimaging evidence of brain abnormalities in mastocytosis. Transl Psychiatry. 2017. PMID 28786975.
3. 3. Novak P, Giannetti MP, Weller E, et al. Mast cell disorders are associated with decreased cerebral blood flow and small fiber neuropathy. Ann Allergy Asthma Immunol. 2022. PMID 34648976.
4. 4. Weinstock LB, Afrin LB, Reiersen A, et al. Prevalence and treatment response of neuropsychiatric disorders in mast cell activation syndrome. Brain Behav Immun Health. 2025. PMID 40686928.
5. 5. Weinstock LB, Nelson RM, Blitshteyn S. Neuropsychiatric manifestations of mast cell activation syndrome and response to mast-cell-directed treatment: a case series. J Pers Med. 2023. PMID 38003876.
6. 6. Afrin LB, et al. Diagnosis of mast cell activation syndrome: a global consensus-2. Diagnosis. 2020. PMID 32324159.
7. 7. Valent P, et al. Proposed diagnostic algorithm for patients with suspected mast cell activation syndrome. J Allergy Clin Immunol Pract. 2019. PMID 30737190.
8. 8. Theoharides TC, et al. Brain "fog," inflammation and obesity: key aspects of neuropsychiatric disorders improved by luteolin. Front Neurosci. 2015. PMID 26190965.
9. 9. Sumantri S, Rengganis I. Immunological dysfunction and mast cell activation syndrome in Long COVID. Asia Pac Allergy. 2023. PMID 37389095.